Roche’s Itovebi™ (inavolisib) significantly improved overall survival in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer patients, according to final Phase III INAVO120 trial results.
Pfizer’s BRAFTOVI® combination regimen has demonstrated a 51% reduction in the risk of death and a 47% decrease in disease progression for patients with BRAF V600E-mutant metastatic colorectal cancer, according to the pivotal Phase 3 BREAKWATER trial.
Sanofi’s real-world study shows that infant immunization with BEYFORTUS® offers stronger protection against RSV-related hospitalizations compared to maternal immunization strategies.
Johnson & Johnson MedTech’s MONARCH™ Platform demonstrated 98.7% navigation success and 83.2% diagnostic yield in the TARGET study, confirming its safety and efficacy for robotically assisted bronchoscopy.
GSK has halted its Phase III PIVOT-PO trial early after an independent review confirmed tebipenem HBr met its primary efficacy goal in treating complicated urinary tract infections, marking a major step forward for oral antibiotic options.
Abbott’s Tendyne™ device has secured FDA approval, revolutionizing mitral valve replacement. This minimally invasive system offers a crucial alternative for high-risk patients with severe mitral annular calcification, eliminating the need for open-heart surgery.
Researchers at Mass General Brigham have developed a promising nasal spray for gene therapy, aiming to deliver treatments directly to the lungs. This innovation could offer a less invasive and more effective approach for genetic lung diseases like cystic fibrosis.
Trastuzumab is a monoclonal antibody that has been engineered to attack and block the human epidermal growth factor receptor 2 (HER2), a protein that contributes to cancer cell growth. It is used most frequently to treat HER2-positive breast cancer and HER2-positive gastric cancer. As [Read More…]
GSK’s Blenrep combinations have received a positive opinion from the CHMP for treating relapsed/refractory multiple myeloma, backed by strong Phase III trial results showing improved survival outcomes.
XTANDI® (enzalutamide), co-developed by Astellas and Pfizer, has shown a significant 30% reduction in risk of death over five years in metastatic hormone-sensitive prostate cancer (mHSPC) patients, marking it as the first androgen receptor inhibitor to demonstrate this long-term survival benefit.
